Bone Marrow Banking for Cell Therapy Material at Scale (Kevin Caldwell, Ossium Health)

<p>In today’s episode, Chris sits down with Kevin Caldwell, CEO, Co-Founder, and President of Ossium Health, a company that aims to improve human health and longevity through bioengineering - specifically using stem cell science to create materials for cell therapies. Together, they discuss Ossium’s approach: processing and banking of bone marrow from organ donors, which can then be cryopreserved and used for various clinical applications such as bone marrow transplants for blood cancer patients and emerging stem cell therapies. Kevin also shares details of his background as a lawyer in the stem cell industry and the potential of stem cell therapies in increasing the availability of bone marrow for treatment options.</p><p>He then goes on to describe his company's clinical programs and their goal of increasing the percentage of patients who ultimately get bone marrow transplants. In addition, he reviews the company's plans for using stem cell therapies in preventive medicine, their focus on improving long-term health and lowering costs, and the company's clinical trial for treating GVHD. Finally, he says a few words about Ossium’s place in the longevity biotech sector.</p><p>Listen in today to not only learn about the potential of stem cell therapies and the importance of increasing the availability of bone marrow for treatment options for blood cancer patients, but to also gain valuable insights into the future of healthcare itself.</p><p><strong>The Finer Details of this Episode:</strong></p><ul><li>Ossium Health and the work it does</li><li>Processing and banking bone marrow from organ donors</li><li>Kevin Caldwell’s professional background</li><li>The potential of stem cell therapies and the impact of increasing the availability of bone marrow</li><li>The clinical applications of cryopreserved bone marrow&nbsp;</li><li>The technicalities and the importance of cryopreservation of bone marrow.</li><li>Ossium Health's clinical programs and their focus on treating patients with acute myeloid and acute lymphoid le